First Time Loading...

China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294

Watchlist Manager
China Resources Boya Bio pharmaceutical Group Co Ltd Logo
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
Watchlist
Price: 34.2 CNY -0.64% Market Closed
Updated: May 16, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

7.8B
-4%
Assets
Growth Rates:
1 Year
-3%
3 Years
+52%
5 Years
+54%
7 Years
+224%
10 Years
+679%
509.1m
-19%
Liabilities
Growth Rates:
1 Year
-40%
3 Years
-52%
5 Years
-63%
7 Years
+56%
10 Years
+140%
7.3B
-3%
Equity
Growth Rates:
1 Year
+2%
3 Years
+78%
5 Years
+98%
7 Years
+250%
10 Years
+824%

Balance Sheet Decomposition
China Resources Boya Bio pharmaceutical Group Co Ltd

7.8B
Assets
509.1m
Liabilities
7.8B
Assets
509.1m
Liabilities
Current Assets 6.4B
Cash & Short-Term Investments 5.3B
Receivables 540.4m
Other Current Assets 575m
Non-Current Assets 1.4B
Long-Term Investments 202.8m
PP&E 684.5m
Intangibles 395.1m
Other Non-Current Assets 118.8m
Current Liabilities 456.4m
Accounts Payable 76.6m
Accrued Liabilities 95m
Short-Term Debt 49.7m
Other Current Liabilities 235.1m
Non-Current Liabilities 52.7m
Long-Term Debt 23.5m
Other Non-Current Liabilities 29.2m

Balance Sheet
China Resources Boya Bio pharmaceutical Group Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
346
699
422
491
1 193
569
754
1 579
1 530
1 950
Cash
0
1
1
1
1
1
1
1 579
1 530
1 950
Cash Equivalents
346
698
421
490
1 192
568
753
0
0
0
Short-Term Investments
0
20
50
0
0
0
0
2 700
3 194
3 362
Total Receivables
82
120
232
597
925
1 010
750
672
668
540
Accounts Receivables
51
91
110
289
543
615
499
445
462
210
Other Receivables
31
29
123
308
382
394
252
227
207
331
Inventory
128
214
289
518
604
621
690
677
667
557
Other Current Assets
47
21
18
149
324
853
734
18
14
18
Total Current Assets
603
1 075
1 011
1 755
3 047
3 053
2 928
5 646
6 073
6 428
PP&E Net
213
453
622
829
873
835
845
783
731
685
PP&E Gross
213
453
622
829
873
835
845
783
731
685
Accumulated Depreciation
162
185
219
256
298
374
410
489
574
556
Intangible Assets
33
105
112
157
235
281
316
273
350
323
Goodwill
127
498
498
664
664
664
664
664
664
73
Note Receivable
0
0
0
0
0
0
0
0
0
36
Long-Term Investments
37
34
84
149
144
133
312
145
118
203
Other Long-Term Assets
6
24
92
116
110
290
95
112
97
82
Other Assets
127
498
498
664
664
664
664
664
664
73
Total Assets
1 018
N/A
2 188
+115%
2 420
+11%
3 670
+52%
5 073
+38%
5 257
+4%
5 159
-2%
7 622
+48%
8 033
+5%
7 829
-3%
Liabilities
Accounts Payable
12
106
86
158
195
172
219
227
270
77
Accrued Liabilities
18
35
55
91
80
91
86
97
125
95
Short-Term Debt
1
24
2
76
178
336
287
50
33
50
Current Portion of Long-Term Debt
0
0
0
22
62
97
55
2
25
1
Other Current Liabilities
56
79
107
370
293
261
225
255
251
234
Total Current Liabilities
87
244
250
716
807
957
872
631
705
456
Long-Term Debt
0
22
22
450
450
269
55
33
10
24
Deferred Income Tax
3
9
9
8
7
7
7
6
6
5
Minority Interest
66
33
39
59
66
77
85
91
99
1
Other Liabilities
4
5
7
11
38
36
32
31
27
24
Total Liabilities
159
N/A
313
+97%
326
+4%
1 244
+281%
1 369
+10%
1 345
-2%
1 051
-22%
793
-25%
848
+7%
509
-40%
Equity
Common Stock
76
267
267
401
433
433
433
512
504
504
Retained Earnings
311
418
636
966
1 370
1 732
1 928
2 259
2 616
2 753
Additional Paid In Capital
471
1 190
1 190
1 059
1 947
1 947
1 947
4 258
4 065
4 063
Treasury Stock
0
0
0
0
46
200
200
200
0
0
Total Equity
858
N/A
1 875
+118%
2 093
+12%
2 426
+16%
3 705
+53%
3 912
+6%
4 108
+5%
6 829
+66%
7 186
+5%
7 320
+2%
Total Liabilities & Equity
1 018
N/A
2 188
+115%
2 420
+11%
3 670
+52%
5 073
+38%
5 257
+4%
5 159
-2%
7 622
+48%
8 033
+5%
7 829
-3%
Shares Outstanding
Common Shares Outstanding
341
401
401
401
433
433
433
512
504
504

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.